One Method Does Not Fit All: A Large-Scale Benchmark of Imputation Methods for Single-Cell RNA Sequencing Data
summary
The gist
We present a comprehensive benchmark of 15 scRNA-seq imputation methods spanning 7 methodological categories, including traditional and DL-based methods.
In short
This study benchmarks 15 single-cell RNA sequencing imputation methods across 30 datasets and 6 downstream analyses. Results show traditional methods often outperform deep learning approaches, but performance varies significantly by task and dataset. The findings guide researchers to choose specific imputation tools based on whether they prioritize numerical accuracy or biological interpretability.
Key concepts
- scRNA-seq Imputation Methods
- These are mathematical techniques used to fill in missing gene expression values in single-cell RNA sequencing data. Because scRNA-seq data is inherently sparse (many zero counts), imputation methods estimate the missing values based on existing information, aiming to create a more complete and accurate representation of the true cell state.
- Downstream Analyses
- These are the biological questions researchers ask after imputing the data. The study evaluates performance in six tasks: numerical gene expression recovery, cell clustering, differential expression (DE) analysis, marker gene identification, trajectory analysis, and cell type annotation. Success depends on how well the imputation preserves these biological signals.
- Traditional vs. DL-based Methods
- Traditional methods rely on established statistical models like smoothing or matrix factorization. Deep Learning (DL)-based methods use neural networks (like GANs or GNNs) to learn complex, non-linear relationships in the data. The benchmark compares these two paradigms to see which is better for different imputation goals.
- Technical Noise and Dropout
- Technical noise refers to errors introduced during sequencing, such as read counts without unique molecular identifiers (UMIs). Dropout refers to the natural biological phenomenon where some genes are expressed at zero in a cell. The study investigates how methods handle these technical issues when evaluating performance across different sequencing protocols.
Terminology used across episodes
This episode discusses
- One Method Does Not Fit All: A Large-Scale Benchmark of Imputation Methods for Single-Cell RNA Sequencing Data · Paper Radio
- Auto-Encoding Variational Bayes
The paper
One Method Does Not Fit All: A Large-Scale Benchmark of Imputation Methods for Single-Cell RNA Sequencing Data · Read on arXiv
RPTU University Kaiserslautern-Landau · German Research Center for Artificial Intelligence (DFKI GmbH) · Graduate School of Informatics, Osaka Metropolitan University · intelligentX GmbH
Transcript
Introduction to the show: ident: Genomics Radio. Generated commentary on the latest computational biology and genomics papers.
Ines: We're looking at the paper: "One Method Does Not Fit All".
Marcus: Here's the gist of the paper. We present a comprehensive benchmark of 15 scRNA-seq imputation methods spanning 7 methodological categories, including traditional and DL-based methods.
Ines: Methods are evaluated across 30 datasets from 10 experimental protocols on 6 downstream analyses.
Marcus: Results show that traditional methods, such as model-based, smoothing-based, and low-rank matrix-based methods, generally outperform DL-based methods, including diffusion-based, generative adversarial network-based, graph neural network-based, and autoencoder-based methods.
Ines: In addition, strong performance in numerical gene expression recovery does not necessarily translate into improved biological interpretability in downstream analyses.
Title and authors: Marcus: Let's talk about the title and who wrote this, which is "One Method Does Not Fit All: A Large-Scale Benchmark of Imputation Methods for Single-Cell RNA Sequencing Data." The title itself tells you the main point upfront.
Ines: It’s a direct statement that there isn't a universal solution for imputing zeros in single-cell data. It sets the stage for why we need this kind of comparison study.
Yuki: From my perspective, it reinforces that biological questions are nuanced; you can't just run the same imputation algorithm and expect the same answer across all species or tissues.
Marcus: The authors are Yuichiro Iwashita, Ahtisham Fazeel Abbasi, Koichi Kise, Andreas Dengel, and Muhammad Nabeel Asim. They’re coming from a mix of computer science departments and research centers that work on artificial intelligence and genomics.
Ines: That mix is interesting because it means they’re looking at the problem from both the computational modeling side and the actual biological data side.
Yuki: I wonder what this means for future population studies; can we trust imputed data when we try to track subtle genetic variation across a large cohort?
Marcus: It suggests that before you run a big imputation pipeline, you need to know which specific downstream task—clustering, trajectory analysis, or maybe just numerical recovery—is your absolute priority.
The paper's summary: Ines: So what does the paper actually summarize? It’s basically showing fifteen imputation methods in six categories against thirty different datasets and protocols to see how they perform across six tasks.
Marcus: They break it down into traditional methods like model based, smoothing based, and low rank matrix based, as well as deep learning approaches like diffusion based, GAN based, graph neural network based, and autoencoder based.
Yuki: And the key finding they push is that traditional methods generally perform better than the deep learning ones in terms of pure numerical recovery of gene expression.
Ines: But here’s the catch they throw in: high performance on numerical recovery doesn't automatically mean better biological interpretability downstream, like when you look at marker gene analysis or cell type annotation.
Marcus: They stress that performance varies a lot depending on the dataset, the protocol used to generate it, and which specific analysis you are running. No single method is consistently best across all scenarios.
Yuki: This is important because if we take a result from one study and apply it to another population with different sequencing depth or capture noise, the results might be totally unreliable.
The paper's improvements: Ines: The paper suggests a few key improvements for how we think about imputation selection. First, you have to select strategies tailored precisely to your analytical objectives rather than just picking the method with the highest overall score.
Marcus: That’s right; they recommend traditional methods like scImpute and MAGIC when you need high fidelity in tasks that require preserving biological meaning, like tracking trajectories or annotating cell types.
Yuki: And for tasks where numerical accuracy is paramount, maybe when you're just trying to get a good estimate of the raw expression levels, WEDGE might be more appropriate.
Ines: They also point out that we need a better way to check for instability; they found that methods using only read counts without unique molecular identifiers, like in SMART-seq datasets, are much less stable.
Marcus: And they noted a specific weakness with some deep learning models; scMultiGAN showed poor correlation with bulk RNA sequence data at both the pseudo bulk and cell line levels, even though it recovered the ground truth data numerically.
Yuki: So the improvement isn't just about finding a better algorithm; it’s about building a framework that tells you what kind of data—read counts versus UMIs—will break which method.
Conclusion: Ines: Wrapping up this whole benchmark, the paper concludes that choosing an imputation method needs to be carefully tailored to the specific downstream task and dataset characteristics. That task-specific evaluation is the most important lesson here.
Marcus: So, for practical application, they recommend scImpute and MAGIC for things like marker gene analysis or trajectory analysis because they seem better at keeping the biological signal intact.
Yuki: For those of us working with large cohorts, this means we have to be very careful about which imputation method we use if we want to make claims about cell types or development pathways across different samples.
Ines: And for me, it’s a reminder that numerical recovery alone isn't enough; you have to check the biological signal preservation alongside the raw numbers.
Marcus: I think this benchmark gives us a clear map of trade-offs between numerical accuracy and biological fidelity across all these different methods. It shows that performance is not uniform.
Yuki: It’s a lot to take in, but it grounds our work in reality; we can't just assume one technique will solve every single data problem without checking the specific conditions first.
Ines: Absolutely. We’ve seen how different approaches handle different noise profiles, and that context is everything when you’re trying to interpret what your scRNA-seq actually tells you about the biology.
More episodes
- 2610.33881-Sensorimotor behavior from an untrained brain-and-nerve-cord connectome
- 2610.40344-Morphological Features of Murine Pulmonary Arterial Networks for Diagnosing Vascular Disease
- Daily Summary for 2026-11-19
- 2609.10193-Are You Learning Biological Signal or Shortcuts? Auditing and Mitigating Bias in Protein-Protein Interaction Datasets
- 2610.38236-Generative discovery of chemical reaction networks
- 2507.11176-An Interpretable AI framework Quantifying Traditional Chinese Medicine Principles Towards Enhancing and Integrating with Modern Biomedicine
- The day in conversation for 2026-11-19
- Daily Summary for 2026-11-19
- 2504.03590-Towards a Unified Framework for Determining Conformational Ensembles of Disordered Proteins
- 2603.15217-A multiscale discrete-to-continuum framework for structured population models